The San Francisco-based company has developed the handheld Cardiospire device to acquire data on cardiogenic oscillation from a patient’s airway to determine whether the patient is approaching congestive heart failure decompensation before experiencing symptoms.
Respirix, which was named one of MedTech Innovator accelerator companies for 2019, told that organization that it “has an opportunity to reduce more than $35 billion of annual costs associated with congestive heart failure hospitalizations in the U.S. alone, and estimated annual costs over $100 billion, with a solution that will be a win for patients, providers and payers.”
Respirix has another $200,000 to raise before reaching its goal, according to the SEC filing.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!